29268-17-5

Upstream product

• 25191-17-7 D-alanine 
• 98-09-9 benzenesulfonyl chloride 
• 338-69-2 D-Alanine 

Downstream Products

• 1072008-41-3 (2R)-N-[5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-39-9 (2R)-N-[5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-43-5 (2R)-N-[5-(4-methylphenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-38-8 (2R)-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-42-4 (2R)-N-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-44-6 (2R)-N-[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 
• 1072008-37-7 (2R)-N-[5-phenyl-1,3,4-thiadiazol-2-yl]-2-[(phenylsulfonyl)amino]propanamide 

Relevant academic research and scientific papers

Thiadiazines and their use as inhibitors of metalloproteinases

The present invention provides novel thiadiazines represented by formula (I) which are useful as inhibitors of metalloproteinases. Also disclosed are pharmaceutical compositions and methods of treating disorders associated with increased activity of metal

Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold

We describe a new generation of heterocyclic nonpeptide matrix metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. A screening effort was utilized to identify some chiral 6-methyl-1,3,4-thiadiazines that are weak inhibitors of